NomuraT, SandilandsA, AkiyamaM, et al.Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007; 119(2):434–440; doi: 10.1016/j.jaci.2006.12.646
2.
SimpsonEL, BieberT, Guttman-YasskyE, et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016; 375(24):2335–2348; doi: 10.1056/NEJMoa1610020
3.
HaginoT, OndaM, SaekiH, et al.Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-week real-world study. Dermatitis. 2025; 36(3):235–243; doi: 10.1089/derm.2024.0323
4.
Lasheras-PérezMA, Palacios-DiazRD, Pozuelo-RuizM, et al.Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Int J Dermatol. 2024; 63(1):105–107; doi: 10.1111/ijd.16926
5.
PezzoloE, NaldiL. Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study. J Eur Acad Dermatol Venereol. 2023; 37(5):e644–e645; doi: 10.1111/jdv.18753
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
